1. Home
  2. PLUG vs VCEL Comparison

PLUG vs VCEL Comparison

Compare PLUG & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Plug Power Inc.

PLUG

Plug Power Inc.

N/A

Current Price

$2.15

Market Cap

2.9B

Sector

Energy

ML Signal

N/A

Logo Vericel Corporation

VCEL

Vericel Corporation

HOLD

Current Price

$37.39

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLUG
VCEL
Founded
1997
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
2.4B
IPO Year
1999
1996

Fundamental Metrics

Financial Performance
Metric
PLUG
VCEL
Price
$2.15
$37.39
Analyst Decision
Hold
Strong Buy
Analyst Count
11
5
Target Price
$2.31
$57.75
AVG Volume (30 Days)
54.0M
428.3K
Earning Date
05-11-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
47.01
60.00
EPS
N/A
N/A
Revenue
$709,919,000.00
$276,259,000.00
Revenue This Year
$26.67
$19.40
Revenue Next Year
$8.09
$18.24
P/E Ratio
N/A
N/A
Revenue Growth
12.90
16.45
52 Week Low
$1.52
$28.95
52 Week High
$4.58
$49.32

Technical Indicators

Market Signals
Indicator
PLUG
VCEL
Relative Strength Index (RSI) 44.82 27.12
Support Level $1.89 $35.45
Resistance Level $2.50 $38.01
Average True Range (ATR) 0.10 1.12
MACD 0.00 -0.34
Stochastic Oscillator 16.07 1.38

Price Performance

Historical Comparison
PLUG
VCEL

About PLUG Plug Power Inc.

Plug Power Inc is building an end-to-end green hydrogen ecosystem, from production, storage, and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets, including material handling, e-mobility, power generation, and industrial applications.

About VCEL Vericel Corporation

Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

Share on Social Networks: